Objective: This study evaluated whether administration of hydroxyethyl starch (HES) 130/0.4 affects coagulation competence and influences the perioperative blood loss. Background: Artificial colloids substitute blood volume during surgery; with the administration of HES 130/0.4 (Voluven, Fresenius Kabi, Uppsala, Sweden) only a minor effect on coagulation competence is expected. Methods: Eighty patients were scanned for enrolment in the study, and 40 patients fulfilled the inclusion criteria. Two patients withdrew their consent to participate in the study, and 5 patients were excluded. Thus, 16 patients were randomized to receive lactated Ringer's solution and 17 to receive HES 130/0.4. Results: Among the patients receiving HES 130/0.4, thrombelastography indicated reduced clot strength (P < 0.001) and blinded evaluation of the perioperative blood loss was 2.2 (range 0.5 to 5.0) versus 1.4 (range 0.5 to 2.4) L in the patients who received HES 130/0.4 or lactated Ringer, respectively (P < 0.038). The patients in the lactated Ringer's group, however, received more fluid (P < 0.0001) than those in the HES 130/0.4 group. There was no significant difference between the 2 groups with regard to frequency of reoperations or the length of hospital stay, but use of HES 130/0.4 was both more expensive and less efficacious than the use of lactated Ringer. Conclusions: Administration of HES 130/0.4 reduced clot strength and perioperative hemorrhage increased by more than 50%, while administration of lactated Ringer's solution provoked an approximately 2.5 times greater positive volume balance at the end of surgery.
erative morbidity is reduced if the amount of volume administered during surgery is adjusted in accordance with flow-related physiological variables. 3 Such individualized goal-directed fluid therapy capitalizes on the finding that for supine humans stroke volume (SV), cardiac output (CO), and thus venous oxygen saturation (SVO 2 ) do not depend on the central blood volume, that is, that a patient is "normovolemic" when the chosen flow-related variable does not respond to further volume administration. 4 During surgery, blood volume is supported by a crystalloid, but up to 30% of the administered crystalloid volume may be lost to the interstitial space even when the circulating blood volume is reduced because of hemorrhage. 5 It remains debatable whether a (usually synthetic) colloid should also be administered even though it remains of concern that synthetic colloids impair coagulation competence by reducing clot propagation and strength. [6] [7] [8] Conversely, synthetic colloids stay in the circulation and may recruit fluid to the vasculature. 5 The ideal fluid substitution therapy affects coagulation competence minimally. Hydroxyethyl starch (HES) 130/0.4 (Voluven, Fresenius Kabi, Uppsala, Sweden) appears to affect coagulation less than other HES products because of its low molecular weight and lower extent of hydroxyethyl substitution. 9 This study evaluated, by using individualized goal-directed volume therapy, whether HES 130/0.4 affects coagulation competence to such an extent that it influences the perioperative blood loss. Patients undergoing cystectomy, which involves noncleavage surgery, were selected to take part in the study because their perioperative loss of blood was considered to depend on coagulation competence. Finally, we evaluated whether there were differences in the cost related to postoperative complications.
METHODS

Trial Design and Oversight
scheduled for elective cystectomy were randomized to receive an empirically defined fixed volume (35 mL/kg) of either lactated Ringer's solution or HES 130/0.4 (Voluven) by computer-generated allocation sequence. A surgical nurse blinded to the randomized fluid registered the volume of blood lost. The conduct of the trial and the safety of the participants were overseen by the authors.
Patients
We included patients older than 18 years with no history of intracerebral hemorrhage, hemodialysis, manifest heart-or hepatic insufficiency, disability of coagulation, or a starch allergy scheduled for elective cystectomy in this study. If a patient used medications that would affect coagulation, those medications were paused 5 days before surgery referring to national guidelines.
Interventions
The included patients were allowed to eat solid foods and to drink clear fluids up to 6 h(ours) and 2 hours before surgery, respectively. An intravenous (IV) catheter was established and flushed with the randomized fluid. This fluid was placed in an opaque bag to ensure blinding of the surgical staff who recorded the volume of lost blood. Monitoring of the patient included noninvasive assessment of blood pressure, pulse oximetry, and electrocardiographic recording. A catheter was placed in the radial artery of the nondominant arm and connected to a Nexfin monitor (Bmeye B.V., Amsterdam, The Netherlands). From the blood pressure curve, Nexfin estimates a beat-to-beat SV and CO by use of a nonlinear 3-component model of arterial impedance by Modelflow. 11 An epidural catheter was inserted (Th interspace 9-12) for postoperative pain treatment, and its placement was tested with 3 mL of lidocaine 2% with epinephrine; epidural anesthesia was established when the operation was completed. With the patient in Trendelenburg's position, a central venous catheter (Edward Lifesciences, Irvine, CA) was inserted, guided by ultrasonography, in the right internal jugular vein using Seldinger technique.
For induction of anesthesia a remifentanil infusion (0.5 μg/kg/ min) was initiated, and when the patient reported sedation propofol (2.0 mg kg-1) was administrated. Propofol (0.4-0.5 mg/kg) and remifentanil (0.3-0.5 μg/kg/min) were used for maintenance of anesthesia with the infusion rate maintained for 10 minutes before each evaluation of cardiac performance. Cisatracurium (0.1-0.15 mg/kg) facilitated oral tracheal intubation, and for ventilation a Dräger CATO (M32040, Lübeck, Germany) in volume-controlled mode was adjusted to aim for an end-tidal CO 2 tension of 28 to 32 mm Hg and a positive end-expiratory pressure of 5 cm H 2 O was used. In the horizontally placed patients, we established normovolemia, that is, we made sure that the SV increased by less than 10% after administration of 200 mL randomized fluid. 3 We noted heart rate, mean arterial pressure, SV, and CO after insertion of the arterial catheter, after establishing normovolemia, after resection of the urinary bladder, at the end of the surgery, and 2 hours thereafter. If the systolic arterial pressure became lower than 80 mm Hg, then 5 to 10 mg of ephedrine was administered. At the same time points, arterial blood was drawn for whole blood viscoelastic hemostatic assay that records clot initiation, formation, and lysis depicting hemostatic competence (thrombelastography; TEG 5000, Hemoscope Corporation, Niles, IL). 12 We analyzed blood for hemoglobin, creatinine, platelets, and fibrinogen and International Normalised Ratio (INR). Furthermore, blood was drawn from the central venous catheter for lactate and blood gas variables (ABL 825, Radiometer, Copenhagen, Denmark). To avoid excessive administration of HES 130/0.4, both groups of patients received either lactated Ringer's solution or human albumin, if considered needed after infusion of 35 mL/kg allocated fluid (nonstudy fluid).
The patient's fluid balance was calculated after cystectomy, at the end of surgery, and 2 hours thereafter. Two surgeons who together completed more than 1000 cystectomies over the last 13 years carried out the procedures.
Outcome
The primary and secondary outcome variables were coagulation competence and perioperative hemorrhage. The third outcome variable was postoperative morbidity and length of hospitalization. Complications during the perioperative period and until discharge from hospital are as follows: respiratory insufficiency due to pneumonia (chest radiography or positive culture), pneumothorax (diagnosed on radiography) or requiring intervention; cardiovascular insufficiency (cardiac arrest, cardiac failure, myocardial infarction); infection requiring antibiotics; surgical complications (site infection, postoperative bleeding or leak requiring reoperation); admittance to intensive care.
Cost-effectiveness Analysis
The cost-effectiveness ratio is defined as the cost per successfully treated patient (ie, cost to keep 1 patient free of complications). The incremental cost-effectiveness analysis was the difference in costs divided by the difference in benefit. 13 Cost of therapy was calculated on the basis of the 2013 prices (Data-Ware-House, Rigshospitalet, Copenhagen, Denmark) of HES 130/0.4 (8.45 $ per 500 mL), lactated Ringer's volume (2.18 $ per 1000 mL), packed red blood cells (86.18 $ per 250 mL), and human albumin 5% (28.70 $ per 250 mL).
STATISTICAL METHODS
We enrolled 40 patients in the study to obtain an 80% power to show a between-group difference of 15% in the primary analysis of blood loss measure at a 2-sided α level of .05. N = (Z a + Z b ) 2 × s 2 / MIREDIF 2 ; we calculated a MIREDIF of 225 and the dispersion s = (2500 − 1000) × 0.95/4 = 356. N = [(1.96 + 0.84) 2 × 126736]/225 2 = 20 patients in each group.
We performed statistical analyses before breaking the randomization code according to the International Conference on Harmonization-Good Clinical Practice guidelines and the statistical analysis plan. 1 The analyses were performed on data from the modified intention-to-treat population, defined as all randomly assigned patients except those who could be excluded without the risk of bias ( Fig. 1 ). Missing data because of withdrawal of consent or surgery without cystectomy were assumed to be independent of treatment. When comparing continuous variables, we used 2-sided or unadjusted χ 2 tests for binary outcome measures and t test and Fisher exact test for continuous and categorical variables, respectively (SPSS version 18.0). Means and standard deviation (SD) are given. A 2-sided P < 0.05 was considered to indicate statistical significance. Coagulation Table 2 presents results from thrombelastography and plasma coagulation analyses. In the HES 130/0.4 group, thrombelastography showed reduced development and strength of the clot (Angle and MA) (P < 0.001), but there was no significant difference in R time or Ly30 between the 2 groups. During surgery fibrinogen and platelets significantly reduced and the reduction was higher in the HES 130/0.4 group (P < 0.01). INR increased significantly in the HES 130/0.4 group compared with the lactated Ringer's group.
Hemorrhage, Use of Blood Products, and Fluid Administration
The perioperatively volume of lost blood was 2181 mL (500-5000) in the HES 130/0.4 group and 1370 mL (480-2375) in the lactated Ringer's group (P = 0.038), Table 3 . This table also presents  administration In the HES 130/0.4 group, patients received in average 33.3 mL/kg (26.9-36.3) HES 130/0.4. Three patients did not receive the full fixed volume scheduled because they were considered to be hemodynamically stable before that volume was infused.
In the HES 130/04 and lactated ringer's group, respectively, the patients with at least 1 treated postoperative complication were 3 (18%) and 5 (31%) whereas those who were reoperated were 1 (6%) and 4 (25%); P = 0.15. The length of hospital stay was 9. 
DISCUSSION
This study evaluated clot strength and perioperative loss of blood with the administration of HES 130/0.4 or lactated Ringer's solution during cystectomy. We optimized the intravascular volume before surgery by means of individualized goal-directed principles. [14] [15] [16] Artificial colloids reduce clot strength by reducing polymerization of fibrinogen producing a clot that contains less fibrin and has less elasticity. 17 During administration of low molecular weight starches, clot strength is impaired, for example, after hip replacement and cardiac surgery. 18, 19 This trial demonstrated impaired coagulation competence by infusion of HES 130/0.4 during cystectomy.
By infusion of HES 130/0.4, we found reduced clot strength at the end of the surgery and, albeit to a lesser extent, also in the recovery ward. Consumption of fibrinogen and platelets were higher in the HES 130/0.4 group, that is, indicating reduced coagulation competence in the HES 130/0.4 group, and results obtained by thrombelastography corresponded to those from plasma coagulation specimens.
Randomized clinical trials show blood loss and transfusion requirements reduced during major surgery with the use of HES 130/0.4 compared with the use of first-and second-generation HESproducts. 20 For treatment of sepsis, HES leads to increased use of blood products during intensive care treatment. 21, 22 When the blood volume lost exceeds 30% (class IV blood loss), the decrease in CO affects oxygen transport to the tissue. 23 The present trial showed increased perioperative hemorrhage when administering the maizebased HES 130/0.4. Moreover, 5 patients (15%) lost more than 2500 mL blood; all were randomized to the HES 130/0.4 group (odds ratio = 14.5, 95% CI = 0.73-28.79, P < 0.05). Yet, in the HES 130/0.4 group, one severely bleeding patient had an injury on the common iliac vein and hemorrhage cannot only be ascribed to the level of coagulation competence in this case. Nevertheless, transfusion requirement increased with administration of HES 130/0.4, but considering the poor outcome with pack red blood cells transfusion, a reduced use of blood transfusions is important. 2 Lactated Ringer's volume reverses the compensatory changes in blood pressure resulting from hypovolemia. Rapid infusion of Ringer's solution is a life-saving treatment for excessive hemorrhage by plasma volume expansion. 24 Conversely, a positive postoperative fluid balance may result in gut edema and contribute to intestinal dysfunction, postoperative complications, and extended hospital stays. [25] [26] [27] We found no significant difference between the 2 groups with regard to morbidity, frequency of reoperations, or hospitalization time, even though the Ringer's group received approximately twice the amount of total fluid during surgery compared with the HES 130/0.4 group. If one treatment is more effective and less costly than another, the one is considered the dominant strategy. The use of lactated Ringer's solution for prevention of complications seems to be a dominant strategy in comparison with the use of HES 130/0.4. This result seems to be consistent with the conclusion of the review by Kruer and Ensor 28 arguing that crystalloids are associated with greater effectiveness and lower costs than do colloids for prevention of morbidity.
The current trial has limitations. For minor surgical procedures, perioperative administration of about 1 L fluid seems rational. 29 Regardless of randomization, however, the incidence of reoperations and length of hospital stay increased in patients with fluid excess, but the study was not powered to evaluate the fluid excess that affects postoperative outcome.
Furthermore, 4 patients (2 patients in each group) were excluded from the trial after randomization as the operation was not completed with cystectomy ( Fig. 1 ).
CONCLUSIONS
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